Research Articles | Page 8 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

  1. Home
  2. Research

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Jan 2021 Leukemia Myelodysplastic Syndromes (MDS)
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Jan 2019 Leukemia Myelodysplastic Syndromes (MDS)
Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study Oct 2023 Leukemia Aplastic Anemia
High-dose Romiplostim Accelerates Hematologic Recovery in Patients With Aplastic Anemia Refractory to Eltrombopag Jul 2020 Leukemia Aplastic Anemia
Myelodysplastic syndromes and the risk of cardiovascular disease in older adults: A SEER-medicare analysis Dec 2019 Leukemia Myelodysplastic Syndromes (MDS)
Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia Mar 2021 Leukemia Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH)
Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes. Jan 2019 Leuk Lymphoma. Myelodysplastic Syndromes (MDS)
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial Aug 2020 Lancet Hematology Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Is there a path forward for immunotherapy in patients with myelodysplastic syndromes? Jan 2024 Lancet Hematology Myelodysplastic Syndromes (MDS)
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study Jan 2024 Lancet Hematology Myelodysplastic Syndromes (MDS)